Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing

[1]  Bas J. Wouters,et al.  Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. , 2017, The Journal of molecular diagnostics : JMD.

[2]  E. Kristiansson,et al.  Patient‐tailored analysis of minimal residual disease in acute myeloid leukemia using next‐generation sequencing , 2017, European journal of haematology.

[3]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[4]  H. Kantarjian,et al.  Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse , 2014, Leukemia & lymphoma.

[5]  J. Shendure,et al.  Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing , 2014, Modern Pathology.

[6]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[7]  L. Bullinger,et al.  Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. , 2013, Blood.

[8]  K. Kinzler,et al.  Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers , 2013, Science Translational Medicine.

[9]  M. Møller,et al.  NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression * , 2011, European journal of haematology.

[10]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[11]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[12]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[13]  B. Falini,et al.  Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia , 2005, Leukemia.

[14]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.